Investment
Features
FeesSafety
Academy
More
Pluang+

Compare SoundHound AI Inc (SOUN) vs 10X Genomics Inc (TXG) Price & Performance

SoundHound AI IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

SoundHound AI Inc vs 10X Genomics Inc — how do they compare? SoundHound AI Inc trades at $6.49 (market cap $2.92B), while 10X Genomics Inc trades at $67.59 (market cap $8.55B). The key difference: 10X Genomics Inc is far larger — about 2.9× SoundHound AI Inc's market cap, and 10X Genomics Inc is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.

SOUNTXG
Market Cap
$2.92B$8.55B
Sector
TechnologyHealth
52-Week High
$21.40$67.29
52-Week Low
$5.70$11.34
Enterprise Value
$2.72B$8.08B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

SoundHound AI Inc

SoundHound AI (SOUN) trades at $6.57, down 2.52% today, with mixed technical signals showing bearish moving averages but bullish oscillators. The company demonstrates strong revenue growth with Q2 2026 revenue up 45% year-over-year to $61.9 million, though it remains unprofitable with a -67.45% net income margin. Recent completion of the LivePerson acquisition creates a leading conversational AI platform with projected 2026 revenue of $230-260 million.

While analyst consensus remains bullish with 75% buy ratings and $8.50 price target (29% upside), significant risks include persistent losses, high valuation multiples (P/S 13.57), and negative cash flow projections for 2026. The stock's heavy short interest (nearly 40%) reflects market skepticism about profitability timeline despite strong top-line growth.

10X Genomics Inc

TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.

The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About SoundHound AI Inc

SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.

Read more on SOUN

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG